Literature DB >> 12702587

Transcriptional gene expression profiling of small cell lung cancer cells.

Nina Pedersen1, Shila Mortensen, Susanne B Sørensen, Mikkel W Pedersen, Klaus Rieneck, Lone F Bovin, Hans Skovgaard Poulsen.   

Abstract

A global gene expression analysis using oligonucleotide microarrays was performed on many human small cell lung cancer (SCLC) cell lines in cell culture and/or as xenografts. The expression was compared with the expression profiles of 18 normal tissues. In a hierarchical cluster analysis the cell lines clustered distinctly from normal tissues and grouped into four clusters. One cluster consisted of two related cell lines and was markedly different from the other SCLC cell lines, whereas the rest of the clusters grouped together. Two subclusters contained the classical SCLC types and one subcluster the variant SCLC type, thus identifying many genes with differential expression between the two variants of SCLC. All of the xenografts clustered closest to the cell lines from which they originated and had the same expression levels as the cells grown in culture for the majority of genes. The analysis confirmed the high expression of many genes identified previously as highly expressed in SCLC cells including neuroendocrine markers, oncogenes, and genes involved in cell proliferation and division. The analysis furthermore identified a number of molecules not identified previously as expressed in SCLC. Several of these are expressed in low or undetectable amounts in the majority of normal tissues and, therefore, are potential targets for new therapeutic approaches. By including the published array profiles of six ressected SCLC tumors from Bhattacharjee et al. (A. Bhattacharjee et al., Proc. Natl. Acad. Sci. USA, 98: 13790-13795, 2001.), the analysis revealed that most of the novel potential targets expressed by SCLC cell lines and xenografts were also expressed in the tumors. This analysis demonstrates the value of using cell lines and xenografts for expression profiling, when a limited quantity of tumor material is available.

Entities:  

Mesh:

Year:  2003        PMID: 12702587

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  37 in total

1.  A DLL3-targeted antibody-drug conjugate eradicates high-grade pulmonary neuroendocrine tumor-initiating cells in vivo.

Authors:  Laura R Saunders; Alexander J Bankovich; Wade C Anderson; Monette A Aujay; Sheila Bheddah; KristenAnn Black; Radhika Desai; Paul A Escarpe; Johannes Hampl; Amy Laysang; David Liu; Javier Lopez-Molina; Milly Milton; Albert Park; Marybeth A Pysz; Hui Shao; Brian Slingerland; Michael Torgov; Samuel A Williams; Orit Foord; Philip Howard; Jacek Jassem; Andrzej Badzio; Piotr Czapiewski; David H Harpole; Afshin Dowlati; Pierre P Massion; William D Travis; M Catherine Pietanza; J T Poirier; Charles M Rudin; Robert A Stull; Scott J Dylla
Journal:  Sci Transl Med       Date:  2015-08-26       Impact factor: 17.956

Review 2.  Insulinoma-Associated-1: From Neuroendocrine Tumor Marker to Cancer Therapeutics.

Authors:  Chiachen Chen; Abner L Notkins; Michael S Lan
Journal:  Mol Cancer Res       Date:  2019-05-21       Impact factor: 5.852

Review 3.  Unravelling the biology of SCLC: implications for therapy.

Authors:  Joshua K Sabari; Benjamin H Lok; James H Laird; John T Poirier; Charles M Rudin
Journal:  Nat Rev Clin Oncol       Date:  2017-05-23       Impact factor: 66.675

4.  Targeted cytosine deaminase-uracil phosphoribosyl transferase suicide gene therapy induces small cell lung cancer-specific cytotoxicity and tumor growth delay.

Authors:  Camilla L Christensen; Torben Gjetting; Thomas T Poulsen; Frederik Cramer; Jack A Roth; Hans S Poulsen
Journal:  Clin Cancer Res       Date:  2010-04-06       Impact factor: 12.531

5.  The effect of adenovirus-mediated gene expression of FHIT in small cell lung cancer cells.

Authors:  Roza Zandi; Kai Xu; Hans S Poulsen; Jack A Roth; Lin Ji
Journal:  Cancer Invest       Date:  2011-12       Impact factor: 2.176

6.  Targeting transcriptional addictions in small cell lung cancer with a covalent CDK7 inhibitor.

Authors:  Camilla L Christensen; Nicholas Kwiatkowski; Brian J Abraham; Julian Carretero; Fatima Al-Shahrour; Tinghu Zhang; Edmond Chipumuro; Grit S Herter-Sprie; Esra A Akbay; Abigail Altabef; Jianming Zhang; Takeshi Shimamura; Marzia Capelletti; Jakob B Reibel; Jillian D Cavanaugh; Peng Gao; Yan Liu; Signe R Michaelsen; Hans S Poulsen; Amir R Aref; David A Barbie; James E Bradner; Rani E George; Nathanael S Gray; Richard A Young; Kwok-Kin Wong
Journal:  Cancer Cell       Date:  2014-12-08       Impact factor: 31.743

7.  Selective inhibition of tumor oncogenes by disruption of super-enhancers.

Authors:  Jakob Lovén; Heather A Hoke; Charles Y Lin; Ashley Lau; David A Orlando; Christopher R Vakoc; James E Bradner; Tong Ihn Lee; Richard A Young
Journal:  Cell       Date:  2013-04-11       Impact factor: 41.582

8.  INSM1 promoter-driven adenoviral herpes simplex virus thymidine kinase cancer gene therapy for the treatment of primitive neuroectodermal tumors.

Authors:  Hong-Wei Wang; Mary B Breslin; Chiachen Chen; Victoria Akerstrom; Qiu Zhong; Michael S Lan
Journal:  Hum Gene Ther       Date:  2009-11       Impact factor: 5.695

Review 9.  Genetic changes in small cell lung carcinoma.

Authors:  Edurne Arriola; Israel Cañadas; Montse Arumí; Federico Rojo; Ana Rovira; Joan Albanell
Journal:  Clin Transl Oncol       Date:  2008-04       Impact factor: 3.405

10.  IA1 is NGN3-dependent and essential for differentiation of the endocrine pancreas.

Authors:  Georg Mellitzer; Stefan Bonné; Reini F Luco; Mark Van De Casteele; Nathalie Lenne-Samuel; Patrick Collombat; Ahmed Mansouri; Jacqueline Lee; Michael Lan; Daniel Pipeleers; Finn C Nielsen; Jorge Ferrer; Gérard Gradwohl; Harry Heimberg
Journal:  EMBO J       Date:  2006-03-02       Impact factor: 11.598

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.